PDUFA VII commitment letter: RWE, rare diseases see renewed attention
Regulatory NewsKari Oakes
Biologics/ biosimilars/ vaccinesChemistry, Manufacturing and Controls (CMC)Clinical TrialsCombination products/companion diagnosticsHealth Authority meeting and communication strategyNorth AmericaPharmaceuticalsProduct LifecycleQuality Assurance and ControlResearch, Design and Development